Bispecific T cell enhancers (BTEs) have proven effective in treating some blood cancers but face challenges in treating some tumors, scientists write. The new CA9-PMTE solves problems by increasing the interaction between T cells and cancer cells, even in “cold” tumors that are not recognized by the immune system.
The study found that delivering synthetic DNA allows the treatment to be produced directly in patients’ bodies, potentially reducing the frequency of treatment and improving treatment outcomes. The innovative design of CA9-PMTE not only increases potency and duration of action but also demonstrates its compatibility with existing immunotherapies.
News materials cannot be equated with a doctor’s prescription. Consult an expert before making a decision.
Source: Ferra
I am a professional journalist and content creator with extensive experience writing for news websites. I currently work as an author at Gadget Onus, where I specialize in covering hot news topics. My written pieces have been published on some of the biggest media outlets around the world, including The Guardian and BBC News.
